TRIALS IN TREATING STIs, VACCINES AND LIPID LOWERING MEDICATIONS
Dr Pi Lip Seet,
Principal Investigator
Paratus Clinical, Brisbane &
Surgical Registrar
Brisbane, Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane | March 2026
Dr Pi Lip Seet graduated from the University of Queensland with a Bachelor of Medicine and Bachelor of Surgery, after completing a Bachelor of Biomedical Science at the University of Newcastle. He has undertaken broad hospital-based training across Queensland and the ACT, with clinical experience in Emergency Medicine, General and Orthopaedic Surgery, Plastic and Reconstructive Surgery, Intensive Care and Coronary Care.
Since joining Paratus Clinical Research in 2022, Dr Seet has served as both Principal Investigator and Sub-Investigator across Phase I–IV industry-sponsored clinical trials. His research experience spans vaccines, immunology, cardiovascular and endocrine disease, respiratory medicine, gastroenterology, pain management, sleep medicine and adult psychiatry. He has been involved in multiple vaccine development programs, including RSV, influenza, COVID-19, herpes zoster and pneumococcal studies.
Dr Seet maintains current Good Clinical Practice certification and advanced life support training. With a strong foundation in acute and procedural medicine, he is committed to delivering high-quality, ethical clinical research, ensuring participant safety while supporting the advancement of innovative therapeutic and vaccine programs.
Source: Supplied
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
-
Food and fasting periods as medicine to prevent disease
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
-
CASE STUDY increasing survival, free of bronchopulmonary dysplasia (BPD) in extremely preterm infants
The aim of the PLUSS trial was to find out if installation of budesonide (a steroid) with surfactant to the lungs of extremely preterm babies helps to prevent lung disease, or Bronchopulmonary dysplasia (BPD).
